## Table 2: ART class at baseline by sex: (A) overall and (B) among the ART naïve1.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **(A) ART class at baseline for n=34,695 participants** | | | | |
|  | **Women**  **N (%)** | **MSM**  **N (%)** | **Non-MSM**  **N (%)** | **P-value** |
| **ART class2** |  |  |  | <0.001 |
| **2-NRTI +INSTI** | 683 (7.8) | 2,466 (15.3) | 839 (8.8) |  |
| **2-NRTI +PI/b** | 4,037 (44.8) | 5,225 (32.3) | 3,974 (41.8) |  |
| **2-NRTI +NNRTI** | 2,831 (31.4) | 5,657 (35.0) | 3,265 (34.3) |  |
| **2 Drug regimen** | 27 (0.3) | 69 (0.4) | 29 (0.3) |  |
| **Other3** | 413 (4.6) | 831 (5.1) | 408 (4.3) |  |
| **No recorded ART**  *at/around baseline4* | 1,028 (11.4) | 1,919 (11.9) | 994 (10.5) |  |
| **Total** | **9,019** | **16,167** | **9,509** |  |
| **INSTI at baseline5** | | | | <0.001 |
| RAL (n, %) | 209 (30.6) | 309 (12.5) | 156 (18.6) |  |
| DTG (n, %) | 330 (48.3) | 1,369 (55.5) | 463 (55.2) |  |
| EVG (n, %) | 79 (11.6) | 526 (21.3) | 113 (13.5) |  |
| BIC (n, %) | 65 (9.5) | 262 (10.6) | 107 (12.8) |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **(B) ART class initiated ≥baseline by sex among n=7,419 ART naïve1.** | | | | |
| **ART class** | **Women**  **N (%)** | **MSM**  **N (%)** | **Non-MSM**  **N (%)** | **Total** |
| 2-NRTI +INSTI | 500 (34.6) | 1,940 (45.6) | 654 (38.0) | 3,094 (41.7) |
| 2-NRTI +PI | 443 (30.6) | 896 (21.1) | 470 (27.3) | 1,809 (24.4) |
| 2-NRTI +NNRTI | 377 (26.1) | 1,087 (25.6) | 446 (25.9) | 1,910 (25.7) |
| Dual regimens | 9 (0.6) | 22 (0.5) | 10 (0.6) | 41 (0.6) |
| Other3 | 30 (2.1) | 118 (2.8) | 20 (1.2) | 168 (2.3) |
| No recorded ART6 | 88 (6.1) | 187 (4.4) | 122 (7.1) | 397 (5.4) |
| **Total** | **1,447** | **4,250** | **1,722** | **7,419** |

1ART naïve: first recorded ART ≥baseline and VL≥200 copies/mL at baseline or no recorded ART and VL≥200 at baseline.

2ART=antiretroviral therapy ongoing at baseline or closest regimen ending within 12-months prior to baseline or commencing within 3-months after baseline. ART class with ≥2-NRTI backbone,2 Drug regimen (2DR) include DTG+3TC, RAL+DRV/b, DTG+DRV/b, DTG + RPV,3TC+DRV/b, RAL+ETV, RAL+NVP, RPV+DRV/b and 3TC+ATV/b. INSTI=integrase strand inhibitor, PI/b=ritonavir or cobicistat boosted protease inhibitor, NNRTI=non-nucleoside reverse transcriptase inhibitor and NRTI=nucleos(t)ide reverse transcriptase inhibitor.

3Other includes multi-class regimens or without ≥2-NRTI backbone.

4 Participant had no recorded ART data within range (described above).

5Percentage of those on INSTI: raltegravir (RAL), dolutegravir (DTG), elvitegravir (EVG) and bictegravir (BIC) at baseline, i.e., 209/683 (30.6%) of women on INSTI at baseline were on a regimen containing RAL.

6No recorded ART with VL≥200 copies/mL at baseline.

Baseline: the latter of 01-Jan-2012 and enrolment into the local cohort.